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TITLE: OCULAR HYPOTENSIVE EFFECTS OF PhXA41 
IN GLAUCOMA PATIENTS AND IOP CHANGE DURING 
DAY AND NIGHT IN NORMAL VOLUNTEERS 
MISHIMA H.K TAKAMATSU M. HIROTA A. and 
KIUCHI Y. 
Department of Ophthahnologv, Universiry of Hiroshima (JP) 
Purpose We evaluated the clinical efficacy of 0.005% PbXA41, a new 
phenyl-substituted prostaglandin Fza-isopropyl ester analogue, in primary 
open angle glaucoma (POAG) and ocular hypertension (OH) patients. We 
also investigated the effect of PhXA41 on diurnal and noctomal IOP 
changes in normal volunteers. 
Methods 1) A multicentral randomized, double-masked study in which the 
effkacy on IOP and safety was evaluated for I2 weeks with daily once 
administration of 0.005% PhXA41 or with daily twice administration of 
il.! Timolol Maleate as a control drug in thirty five patients with POAG or 
2) Sixteen normal volunteers were recruited for the study to evaluate the 
diurnal and nocturnal change of IOP with daily once administration of 
0.005% PhxA41. 
Results The mean IOP reduction from baseline after 12 weeks treatments 
6.2*2.7 mmHg for PhXA41 and 4.4k2.3 mmHg for Timolol Male&c, 
respectively. The mean IOP reduction of PhXA41 group was greater than 
the other one. Major symptoms were only conjunctival hyp=eremia and 
smarting in both groups. PhXA41 kept reducing IOP with daily once 
administration either in day and night. 
Condusiom 1) PhXA41 showed significantly better IOP reduction than 
Tim0101 Maleate. 2) PhXA41 reduces the IOP in normal volunteers with 
daily once administration either in day and night. 
COMPARISON OF MITOMYCIN C AND 5 FLUOROURACIL IN 100 
CASES OF HIGH RISK TRABECULECTOMIES. 
of Purpose: A comparison of long term effect on IOP and complications 
trabeculectomies performed with the adjunct of either postoperative 5 
fluorouracil(5FU) or peroperative mitomycin C(MMC) in 100 cases of high 
risk glaucoma. 
&&&We prospectwly studied 52 eyes of46 patients treated with MMC 
(Follow up 15i8.7111) and compared it with a retrospective scrie of48 eyes 01 
35 patients treated with 5FU (Follow up 14,3li 11,25m). 
&w&84% of MMC patients but 46% of 5FU group had a normalized 101’ 
without treatment, and 23% of 5FU vs 5,7 % of MMC patients required 
systemic glaucoma therapy. Early adverse effects were more’frequently 
observed with 5FU (cornea 39%, conjonctiva 17% or hypotony 29%) than 
with MMC (13,46%, 3,85%,13,46% rcspectivly). At last examination, bleb 
failure requiring additional surgery was more frequent in 5FU group (10%) 
than MMC (3%), and was mostly associated to anterior chamber factors (i.e. 
vitreous or lens rclatcd obstruction), rnthcr than cpisclcrnl cclluln~ 
li~c~owl.o~~g km hypotony was obscrvcd in il l 17.3 % ol the MMC cycs. in 
this later group 5 of 9 patients had more than 2 lines of best corrected visual 
acuity reduction. 
Conclusion: l’hesc results suggest that MMC is ot Icut as cl’licicnt 10 
reduce lOP.The use of MMC may be associated with a higher rate of long 
term hypotony. 
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INTRAOPERATIVR TREATMENT WITH MITOMYCIN C IN 
EXPERIMENTAL GLAUCOMA FILTERING SURGERY: 
DOSE EFFECT ON CONJUNCTIVAL AND SCLERAL 
FIBROBLASTS. 
PINILLA I.’ LARROSA JM.’ ABECIA E.’ POLO V.’ 
RAMIREZ T? LANA!3 A.3 HONRIJBIA F&L1 
1 Department of Ophthalmology. Miguel Servet Hospital. Zaragoza. 
Spain. 
2 Department of Pathology. Miguel Set-vet Hospital. Zaragoza Spain. 
3 Mixed Investigation Unit. University of Zaragoza. Spain. 
PURPOSE: To evaluate the effect of mitomycin C on fibroblasts 
outgrowth in a model of glaucoma filtering squy. 
METHODS: pigment rabbits undergoing iXermg surgery were exposed to 
several intraopemtive treatments: Group 1 (n=S): balanced saline solution; 
Group 2 (n=5): mitomycin C 0.2 mg/ml: Group 3 (n=S): mitomycin C 0.4 
mg/mI. Tissue samples were taken one hour after surgery and included 
conjunctival and scleral tissue at 00 and 90° area and the adjacent cornea 2 
mm from the Iimbus. The biopsies were placed in tissue culture media 
(trimix media with 2oRo fetal calf serum) and incubated at 370 and PC@ 
5%. in a humified atmosphere. Fibmblast outgrowths were measured 
every 3 days for 12 days: cell morphology was evaluated as well. 
Repeated-measures analysis of variance was performed each time. 
Sieniticance was defined as wO.05. 
RI?SULTS: The average &era1 and conjunctival outgrowth from the. 
mitomycin-C treated tissues WCR sigaificantly lus than the outgrowth of 
the eyes treated with BSS, throughout aII the experiment to day 12. The 
outgrowths from the 90’ tissues of mitomycin treated eyes, were 
signiticaa~y higher than 0” tissues and similar to BSS group. There were 
no differences behveen eyes treated with mitomycin 0.2 mg/mI and eyes 
treated with mitomwin 0.4 ma/ml at aw time. tint. The cells arowina out 
from the mitomycbi C Wated -&as we&abn&al in appcamndz. - 
The oatgrowths anneal samples were similar in all group. 
CONCLUSIONS: Intracperative exposure to mitomycin C has an 
on the local conjunctival and s&d l%mbl&appulation. 
effect is similar with mitomycin 0.2 and 0.4 mg/ml. 
tment-induces abnormal tibmblaab morphology. 
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